5,325 Shares in Astera Labs, Inc. $ALAB Acquired by Daiichi Life Insurance Co. Ltd.

Daiichi Life Insurance Co. Ltd. acquired a new position in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,325 shares of the company’s stock, valued at approximately $2,572,000.

A number of other institutional investors have also recently bought and sold shares of ALAB. Vanguard Group Inc. grew its stake in shares of Astera Labs by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 13,827,506 shares of the company’s stock valued at $2,300,344,000 after buying an additional 84,365 shares during the period. BlackRock Inc. acquired a new stake in shares of Astera Labs in the second quarter valued at about $6,609,581,000. Atreides Management LP grew its position in Astera Labs by 108.9% in the first quarter. Atreides Management LP now owns 3,365,787 shares of the company’s stock valued at $368,890,000 after acquiring an additional 1,754,593 shares in the last quarter. State Street Corp grew its holdings in Astera Labs by 32.5% during the 4th quarter. State Street Corp now owns 3,099,809 shares of the company’s stock valued at $515,684,000 after purchasing an additional 760,358 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Astera Labs by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 2,429,078 shares of the company’s stock worth $403,598,000 after acquiring an additional 104,935 shares during the last quarter. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Jitendra Mohan sold 90,630 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $340.35, for a total value of $30,845,920.50. Following the transaction, the chief executive officer directly owned 1,266,665 shares in the company, valued at approximately $431,109,432.75. This trade represents a 6.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jack R. Lazar sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $355.17, for a total transaction of $3,551,700.00. Following the completion of the transaction, the director directly owned 75,688 shares in the company, valued at $26,882,106.96. This represents a 11.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 419,244 shares of company stock worth $163,135,169. Company insiders own 10.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Royal Bank Of Canada lifted their price target on shares of Astera Labs from $425.00 to $500.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. Citigroup reissued a “buy” rating on shares of Astera Labs in a research report on Wednesday, July 29th. Bank of America upped their target price on shares of Astera Labs from $240.00 to $450.00 and gave the company a “neutral” rating in a research note on Tuesday, June 23rd. Susquehanna increased their price target on shares of Astera Labs from $230.00 to $275.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. Finally, Zacks Research upgraded Astera Labs from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $333.00.

Astera Labs Stock Performance

ALAB stock opened at $284.97 on Monday. The stock’s 50 day simple moving average is $352.70 and its 200 day simple moving average is $245.57. Astera Labs, Inc. has a 12-month low of $97.89 and a 12-month high of $499.48. The firm has a market cap of $49.44 billion, a P/E ratio of 141.07 and a beta of 3.84.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.11. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The firm had revenue of $392.40 million during the quarter, compared to the consensus estimate of $360.85 million. During the same quarter in the previous year, the company posted $0.44 earnings per share. The firm’s revenue was up 104.5% on a year-over-year basis. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. On average, research analysts forecast that Astera Labs, Inc. will post 2.7 EPS for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.